Neptune Acquires Common Shares of Acasti Pharma

Neptune Technologies & Bioressources (Nasdaq: NEPT) announces that on February 10, 2012 it acquired 750,000 newly issued Class "A" common shares in the capital of Acasti Pharma Inc., a subsidiary of Neptune. The Shares were acquired at a price of $1.33 CAD per Share for an aggregate consideration of $1,000,000 CAD pursuant to a subscription agreement entered into with Acasti which contained customary terms and conditions. The Subscription Agreement was entered into as part of a private placement of Shares pursuant to which Acasti raised approximately $2,000,000 CAD.

Before the closing of the Private Placement, Neptune held 40,617,733 Shares, representing 57% of the issued and outstanding Shares in the capital of Acasti at that time. After completion of the Private Placement, Neptune now has beneficial ownership and control over 41,367,733 Shares, representing 57% of the issued and outstanding Shares in the capital of Acasti. Following Neptune investment the Corporation will potentially hold more than 50% of the fully diluted number of Shares of Acasti.